Merve Dede (@drmervedede) 's Twitter Profile
Merve Dede

@drmervedede

Physician, now also a PhD in MD Anderson Cancer Center

ID: 276680133

calendar_today03-04-2011 21:27:12

215 Tweet

157 Followers

402 Following

Colm Ryan (@colmr) 's Twitter Profile Photo

delighted to see Barbara De Kegel's work out in Mol Syst Biol! Tumors tolerate astonishing numbers of genetic alterations, including homozygous deletion of entire protein coding genes. How? Here we explored one potential explanation – paralog dispensability! embopress.org/doi/full/10.15…

Colm Ryan (@colmr) 's Twitter Profile Photo

perspective piece in Nature Genetics with Lovely Paul Solomon Devakumar Steve Pettitt and @IcrLordLab. Thinking of synthetic lethality in cancer as a two-gene phenomenon is limiting. Environmental & other genetic factors are likely to play a significant role rdcu.be/dsrzs

Katy Rezvani, M.D., Ph.D (@lab_rezvani) 's Twitter Profile Photo

Please check out our paper published in Nature Medicine on our Phase I / II trial with cord blood CAR19/IL15 NK cells. We report promising 1 year PF and OS rates of 32% and 68% in patients with relapsed / refractory B cell malignancies (with a median of 4 prior lines of

May Daher (@may_daher) 's Twitter Profile Photo

A labor of love and a true testament to team effort! I hope you enjoy reading it as much as we enjoyed working on it. This work highlights the importance of donor selection for cell therapy; not all donors are created equal! Katy Rezvani, M.D., Ph.D @Yl668Li Rafet Hind Rafei

Hind Rafei (@hindrafei) 's Twitter Profile Photo

Our team is delighted to share with you our most recent work on importance of donor selection for allogeneic CAR NK cell therapy! A true team effort with great leadership 🤩😊! Great progress for our patients! @Yl668Li Rafet May Daher Katy Rezvani, M.D., Ph.D MD Anderson Cancer Center #CARNK

NEJM (@nejm) 's Twitter Profile Photo

Patients with evidence of microplastics and nanoplastics in carotid artery plaque, as compared with patients without, had a greater risk of adverse cardiovascular events at 34 months of follow-up. Read the full article: nej.md/3IrM6T8

Patients with evidence of microplastics and nanoplastics in carotid artery plaque, as compared with patients without, had a greater risk of adverse cardiovascular events at 34 months of follow-up. Read the full article: nej.md/3IrM6T8
Rafet (@rftbsr9) 's Twitter Profile Photo

Presenting at the ESH (Haematology) conference today on off-the-shelf CAR NK cell therapies was an absolute delight. A very comprehensive program featuring insightful presentations by experts in the field.

Ken Chen (@kchenken) 's Twitter Profile Photo

Forecasting Acute Kidney Injury and Resource Utilization in ICU patients using longitudinal, multimodal models medrxiv.org/content/10.110… Our continued efforts in exploring how AI/ML can be applied in medicine. Merve Dede Yukun Tan

Ken Chen (@kchenken) 's Twitter Profile Photo

Proud ⁦KChenLab⁩ scored #1 in the subtask 2 of this international AI medicine challenge. It took an AI engineer ⁦Yukun Tan⁩ and a medical doctor ⁦Merve Dede⁩ working closely in our team. Both technology and knowledge mattered. sites.google.com/view/chemotime…

Ken Chen (@kchenken) 's Twitter Profile Photo

Forecasting acute kidney injury and resource utilization in ICU patien... sciencedirect.com/science/articl… Our recent work that applies multimodal AIs to forecast disease occurrence and resource utilization in ICU. šŸ¤ Merve Dede Yukun Tan

Thomas Gonatopoulos-Pournatzis (@tgonatopoulos) 's Twitter Profile Photo

Check out our CRISPR genome-scale exon perturbation study Molecular Cell. We identified exons influencing cell fitness and uncovered a novel mechanism by which #splicing affects #transcription. Michael Aregger Arun Prasath Damodaran Meisheng @NCIResearchCtr NIH doi.org/10.1016/j.molc…

Hind Rafei (@hindrafei) 's Twitter Profile Photo

Please check out our recent ā€œIn a Nutshellā€ article for brief updates on CAR-NK cell therapy for cancer. Lots of new exciting frontiers in the field! ⁦Katy Rezvani, M.D., Ph.D⁩ ⁦MD Anderson Cancer Center⁩ ⁦British Journal of Haematology⁩ #CARNK #NK #Cell therapy. onlinelibrary.wiley.com/doi/abs/10.111…

Ken Chen (@kchenken) 's Twitter Profile Photo

Thanks Cell Reports Methods for performing very professional review. Our work shows that cells transitioning into new transcriptional state in development or differentiation can be detected statistically via gene expression correlations in single cell rna-seq. Kudos Merve Dede etc

Ken Chen (@kchenken) 's Twitter Profile Photo

Our preprint that performs virtual NK adoptive cell therapy using agent based modeling can potentially guide cell therapy development and decision support. biorxiv.org/content/10.110…

Ken Chen (@kchenken) 's Twitter Profile Photo

We developed immune cell knowledge graphs (ICKGs) using LLMs to understand and annotate novel gene signatures identified from single-cell/spatial omics studies biorxiv.org/content/10.110…

Feng Zhang (@zhangf) 's Twitter Profile Photo

We are excited to report the discovery of TIGRs, a widely-occurring RNA-guided system found in bacteria and their viruses. TIGRs consist of a peculiar repeat region which is transcribed into RNA and processed into multiple guide RNAs to direct TIGR-associated proteins to their

Katy Rezvani, M.D., Ph.D (@lab_rezvani) 's Twitter Profile Photo

Brilliant work! congratulations, May Daher and simona colla and co-authors. Fascinating insight into how early NK cell dysfunction contributes to immune escape in MDS, and a compelling case for the therapeutic potential of adoptive NK cell transfer. Looking forward to seeing

MD Anderson Cancer Center (@mdandersonnews) 's Twitter Profile Photo

This morning at #AACR25, our Dr. Katy Rezvani shared an overview of her team’s wide-ranging CAR NK cell platform targeting hematological malignancies and solid tumors, leading to 12 ongoing clinical trials. Katy Rezvani, M.D., Ph.D AACR #EndCancer

This morning at #AACR25, our Dr. Katy Rezvani shared an overview of her team’s wide-ranging CAR NK cell platform targeting hematological malignancies and solid tumors, leading to 12 ongoing clinical trials. <a href="/lab_rezvani/">Katy Rezvani, M.D., Ph.D</a>  
<a href="/AACR/">AACR</a> #EndCancer
Merve Dede (@drmervedede) 's Twitter Profile Photo

Congratulations Hind Rafei, Katy Rezvani, M.D., Ph.D and everyone else on the team for this great paper! This was truly an exciting project to work with alongside so many great researchers. Looking forward to future collaborations.